Solorank.ai
Login

Cached score snapshot

US.RVTY · Revvity

110分制 72/110；5D動能v2 11/50；排序分 83/160

Back to ranking Open volume snapshot
Ranking score 83/160
Main score 72/110
5D momentum v2 11/50
Rank #39
Setup grade D 42

Score breakdown

謹慎買入

Medium twelvedata

Score and price trend

D 42 Money flow S · Technical A · Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-29 07-23 09-01 09-17 10-05 $93.55$117.56$141.57 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.547 · anchors 120 +0.34% -1.06% / +2.62% 60% 2.5% Actual +5.46% · vs median +5.12% · inside 25-75 band
30D observation +6.42% +2.66% / +9.40% 90% 0% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.61% -1.69% / +3.05% 59.4% 3.8% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-05-29 → 2026-10-05 · 148 archived points · 2 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 83
Display grade 謹慎買入
Model version cursor_18_27_news_v2_160
Main score 72/110 (謹慎買入)
5D momentum v2 11/50 (弱)
Score with momentum v2 83/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 116.3345
ma50 111.609
close 123
prevClose 124.75
avgVolume20 1615718
volumeRatio 0.93
changePercent -1.4

Metrics snapshot

close 123
volume 1505356
changePercent -1.4

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 72/110
Main rating 謹慎買入
5D momentum v2 11/50
Score with momentum v2 83/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.4/5 · 較差
Dimension score 2.4/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.2
epsPoints 0
roePoints 0
debtPoints 0.5
marginPoints 0
turnoverUsdM 185.1588
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.4

資金流 — 16.4/20 · 優秀
Dimension score 16.4/20
Dimension grade 優秀

Sub-items

cmfPoints 4
mfiPoints 4
obvPoints 2.4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.RVTY
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 8/15 · 較差
Dimension score 8/15
Dimension grade 較差

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 15.13

trend

score 1.8

details

qqq

ma20 710.3985
ma50 713.2256
name QQQ
close 706.32
points 0.4

spy

ma20 763.546
ma50 752.2638
name SPY
close 763.47
points 1.4
source twelvedata+fred
atrPct 2.8972
atrPoints 3
cciPoints 0.8
vixPoints 2.4
marketTrendPoints 1.8

催化劑 — 10/20 · 較差
Dimension score 10/20
Dimension grade 較差

Sub-items

catalyst

score 10

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 2
catalystPoints 10

風險管理 — 6.6/10 · 一般
Dimension score 6.6/10
Dimension grade 一般

Sub-items

position

score 1.4

details

atrPct 2.8972
turnoverUsdM 185.1588
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.RVTY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 115.8728

strength_details

ma_score 1.5
atr_score 2
rsi_score 0.5
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 5.8
take_profit_price 130.4479
target_multiplier 1.9
technical_strength 1.65
take_profit_percent 6.1
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.7945
diversificationPoints 2

技術信號 — 22.6/30 · 良好
Dimension score 22.6/30
Dimension grade 良好

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 2.7
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 2.7
vcp_reason 波幅收縮(18.4%→10%)；跌縮量(近10日5日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=N

vcp_metrics

up_days 4
vol_ref 1488173.3333
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 1384160
avg_vol_20 1607905
avg_vol_30 1488173.3333
range_pct_10 0.0999
range_pct_20 0.1422
range_pct_30 0.1837
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 3
breakout_20d_ok false
vol_ratio_10_30 0.9301
dist_to_20d_high 0.0158
down_shrink_days 5
breakout_level_20d 124.97
vcp_breakout_confirm false
contraction_ratio_10_30 0.5438
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.7
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 6/10 · 一般
Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 4
sentimentScoreRaw 1.2

sentimentData

raw {"id":141202718,"url":"https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Diagnostics surged 11% organically as AI-driven demand accelerated.","category":"company","datetime":1786468489,"headline":"Revvity (RVTY) Q2 2026 Earnings Call Transcript"}, {"id":141130140,"url":"https://finnhub.io/api/news?id=3b09f71f2cbab477f19820a3c1615fbcc87b1cb019802ccf7fd9d75767be6a7e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...","category":"company","datetime":1785975423,"headline":"Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?"}, {"id":141114964,"url":"https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.","category":"company","datetime":1785870540,"headline":"RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"}, {"id":141113403,"url":"https://finnhub.io/api/news?id=6de21f8800fe1d28710bef6901b16a8e423b3c72a548d7a79f771209813ac706","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.","category":"company","datetime":1785870203,"headline":"Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ..."}, {"id":141112526,"url":"https://finnhub.io/api/news?id=f8e2926aa47753dd15c45680ad760e5f6677eb2f3492332a5c7f6542c12951fa","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RVTY","summary":"Revvity, Inc. (RVTY) Q2 2026 Earnings Call August 4, 2026 7:30 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor Relations & Head of...","category":"company","datetime":1785854998,"headline":"Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript"}, {"id":141108193,"url":"https://finnhub.io/api/news?id=238f072ead1f61789f2adad88d3f819a922309996a3e11aea9ad474b5efb29e9","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp","source":"ChartMill","related":"RVTY","summary":"Revvity (RVTY) Q2 adjusted EPS beats at $1.41, revenue in line; pro forma FY26 revenue guidance below consensus, stock premarket -0.2%.","category":"company","datetime":1785847220,"headline":"Revvity (NYSE:RVTY) Beats Q2 EPS Estimates, but Soft Revenue Guidance Caps Stock Reaction"}, {"id":141108945,"url":"https://finnhub.io/api/news?id=727bdd59352e12f5370f3d9aa1251b4ff5220074e984a861af0bb151406036b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) delivered earnings and revenue surprises of +14.63% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785842703,"headline":"Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates"}, {"id":141107927,"url":"https://finnhub.io/api/news?id=18c76b227e811cf03590ccb4621a41dfa2eb6c1a394365398cb37b7e9d3264f0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.","category":"company","datetime":1785838250,"headline":"Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026"}
raw_source {"id":141263724,"url":"https://finnhub.io/api/news?id=79817c6765abca477c158dde61718bc04fe3d602b4fecbff929b0a7fcd1bb05a","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.","category":"company","datetime":1787252701,"headline":"Exploring the top movers within the S&P500 index during today's session."}, {"id":141230562,"url":"https://finnhub.io/api/news?id=4d092ebe3aa6f83822c04a961bb022d30ba76830344f6c5fdbe0e95de91c9b2a","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1786857318,"headline":"Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside"}, {"id":141218677,"url":"https://finnhub.io/api/news?id=652224e6eaeca65523b7fcc05076da4b572b7f65213dd09624d1398b823f11df","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1786721166,"headline":"Danaher: 2027 Growth Reacceleration Should Drive Upside"}, {"id":141206709,"url":"https://finnhub.io/api/news?id=abf15460060e9d68def7ae24c3778a414925e71cb70a7b8f3956a47e4e500adc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.","category":"company","datetime":1786629600,"headline":"Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs"}, {"id":141202717,"url":"https://finnhub.io/api/news?id=e2a2e352b10892b67e53ab7554bbeb3ba8baff2bbefdfaba1a2267691b1082dd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to \"tangible signs of a more constructive spending environmen","category":"company","datetime":1786587660,"headline":"The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call"}, {"id":141202718,"url":"https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Diagnostics surged 11% organically as AI-driven demand accelerated.","category":"company","datetime":1786468489,"headline":"Revvity (RVTY) Q2 2026 Earnings Call Transcript"}, {"id":141202719,"url":"https://finnhub.io/api/news?id=c4fbd63bd68321a1fd0751f6671df4d112f0dbc162a5bed08991df064ba072e3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:","category":"company","datetime":1786449600,"headline":"Revvity to Present at Upcoming Investor Conferences"}, {"id":141174464,"url":"https://finnhub.io/api/news?id=63dd3feb8ba49e1ae84ce6a141b45b7a3b89f86583deb193b3dea0bea2fb5247","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.","category":"company","datetime":1786363200,"headline":"Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing"}, {"id":141173746,"url":"https://finnhub.io/api/news?id=40b71ceb7b13d365c949f86e7e49081f3457d6ee7e752ab19caba47ee97b41d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.","category":"company","datetime":1786360642,"headline":"1 Profitable Stock on Our Buy List and 2 We Find Risky"}, {"id":141164551,"url":"https://finnhub.io/api/news?id=28240c7696bd84e8c1650ca65c32607de843b27341b0f3371fb567d0795f9fd1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows","category":"company","datetime":1786248230,"headline":"Revvity Q2 Earnings Call Highlights"}, {"id":141130140,"url":"https://finnhub.io/api/news?id=3b09f71f2cbab477f19820a3c1615fbcc87b1cb019802ccf7fd9d75767be6a7e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...","category":"company","datetime":1785975423,"headline":"Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?"}, {"id":141124751,"url":"https://finnhub.io/api/news?id=60ed1972b305bdd36e0186e5a542aaa8a808486d5b0617cd0227d8d1979e0d48","image":"","source":"Benzinga","related":"RVTY","summary":"Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.","category":"company","datetime":1785929351,"headline":"Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126"}, {"id":141120490,"url":"https://finnhub.io/api/news?id=327874635803840701afed49e7a414cbbd8124be013f75fc7953604475646b8f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Moby summary of Revvity, Inc.'s Q2 2026 earnings call","category":"company","datetime":1785893627,"headline":"Revvity, Inc. Q2 2026 Earnings Call Summary"}, {"id":141114964,"url":"https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.","category":"company","datetime":1785870540,"headline":"RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"}, {"id":141112773,"url":"https://finnhub.io/api/news?id=014a623496be595444b2cd0b07829ee26470d3fd42a2b03f046b0558238ac22f","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.","category":"company","datetime":1785870301,"headline":"These S&P500 stocks are moving in today's session"}, {"id":141113403,"url":"https://finnhub.io/api/news?id=6de21f8800fe1d28710bef6901b16a8e423b3c72a548d7a79f771209813ac706","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.","category":"company","datetime":1785870203,"headline":"Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ..."}, {"id":141110787,"url":"https://finnhub.io/api/news?id=a5adcb4f64fad6b04cbe165f0115f21602739e6b7b55d969e069991ad09d0aff","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.","category":"company","datetime":1785861301,"headline":"Discover which S&P500 stocks are making waves on Tuesday."}, {"id":141112950,"url":"https://finnhub.io/api/news?id=3c1b90a21300a2c6586eff847edd8a9324cd28249584478e18e22959571d9857","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RVTY","summary":"2026-08-04. The following slide deck was published by Revvity, Inc.","category":"company","datetime":1785857544,"headline":"Revvity, Inc. 2026 Q2 - Results - Earnings Call Presentation"}, {"id":141112526,"url":"https://finnhub.io/api/news?id=f8e2926aa47753dd15c45680ad760e5f6677eb2f3492332a5c7f6542c12951fa","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RVTY","summary":"Revvity, Inc. (RVTY) Q2 2026 Earnings Call August 4, 2026 7:30 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor Relations & Head of...","category":"company","datetime":1785854998,"headline":"Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript"}, {"id":141109361,"url":"https://finnhub.io/api/news?id=25ddbd348ba31eb1ce7b528ec93a8bd8c2ccf96782356409174df68b59475a7a","image":"https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp","source":"ChartMill","related":"RVTY","summary":"Let's have a look at the S&P500 gap up and gap down stocks in today's session.","category":"company","datetime":1785854101,"headline":"Gapping S&P500 stocks in Tuesday's session"}, {"id":141108193,"url":"https://finnhub.io/api/news?id=238f072ead1f61789f2adad88d3f819a922309996a3e11aea9ad474b5efb29e9","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp","source":"ChartMill","related":"RVTY","summary":"Revvity (RVTY) Q2 adjusted EPS beats at $1.41, revenue in line; pro forma FY26 revenue guidance below consensus, stock premarket -0.2%.","category":"company","datetime":1785847220,"headline":"Revvity (NYSE:RVTY) Beats Q2 EPS Estimates, but Soft Revenue Guidance Caps Stock Reaction"}, {"id":141108944,"url":"https://finnhub.io/api/news?id=7ede018240307bd8082d76ee22eecddebdc2adfc08739acfb307125d65e8497e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity, Inc. (NYSE:RVTY) reported second-quarter 2026 results that exceeded Wall Street expectations, prompting the health sciences company to raise its guidance for the full year.","category":"company","datetime":1785846234,"headline":"Revvity Tops Second-Quarter Estimates and Lifts Full-Year Outlook"}, {"id":141108945,"url":"https://finnhub.io/api/news?id=727bdd59352e12f5370f3d9aa1251b4ff5220074e984a861af0bb151406036b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) delivered earnings and revenue surprises of +14.63% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785842703,"headline":"Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates"}, {"id":141107927,"url":"https://finnhub.io/api/news?id=18c76b227e811cf03590ccb4621a41dfa2eb6c1a394365398cb37b7e9d3264f0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.","category":"company","datetime":1785838250,"headline":"Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026"}, {"id":141107928,"url":"https://finnhub.io/api/news?id=05a9c470ebcc5ee4fe1783b5505884a609f9c0555e10ea66c747d186160b601f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., August 04, 2026--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026.","category":"company","datetime":1785837600,"headline":"Revvity Announces Financial Results for the Second Quarter of 2026"}, {"id":141111290,"url":"https://finnhub.io/api/news?id=a7855707df97a256f43b7df721858f745da5a70746db0b56be898a0f0070be4f","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/movers_1.jpg?width=2048&height=1536","source":"Benzinga","related":"RVTY","summary":"Revvity (NYSE:RVTY) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.\nBenzinga APIs provide real-time access to earnings call transcripts and financial data.","category":"company","datetime":1785832496,"headline":"Transcript: Revvity Q2 2026 Earnings Conference Call"}, {"id":141111291,"url":"https://finnhub.io/api/news?id=604e9ed9d00764322ba0a23e6be76962169a7fd5ac737b75d4eaae0d1ddf1bd0","image":"","source":"Benzinga","related":"RVTY","summary":"Revvity (NYSE:RVTY) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst estimate. Raises FY2026 sales outlook from $2.810 billion-$2.840 billion to $2.830 billion-$2.860 billion vs $2.858","category":"company","datetime":1785823346,"headline":"Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 Sales Guidance from $2.810B-$2.840B to $2.830B-$2.860B vs $2.858B Est"}, {"id":141111292,"url":"https://finnhub.io/api/news?id=a53a734a448eea14c2936b678d1c906fc5fe577a9ef7a904a578fc75abb02862","image":"","source":"Benzinga","related":"RVTY","summary":"Revvity (NYSE:RVTY) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.22 by 15.57 percent. This is a 19.49 percent increase over earnings of $1.18 per share from the same","category":"company","datetime":1785823231,"headline":"Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate"}, {"id":141097939,"url":"https://finnhub.io/api/news?id=aa35a1e05ff68cc1bfdd32b254910d10f4931cfb4236921bcf0fa7d612164a60","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.","category":"company","datetime":1785737122,"headline":"Revvity (RVTY) To Report Earnings Tomorrow: Here Is What To Expect"}, {"id":141082732,"url":"https://finnhub.io/api/news?id=6fde63646961578709f68511bafd15d6c771b7b43147b073927253211b00b740","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., July 31, 2026--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.","category":"company","datetime":1785528300,"headline":"Revvity Board Declares Quarterly Dividend"}, {"id":141076727,"url":"https://finnhub.io/api/news?id=0e9254108a2c029aad9057d72fb6d4e849f4a4c203f61703868c920087b76714","image":"https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp","source":"ChartMill","related":"RVTY","summary":"Revvity (RVTY) shows a strong technical breakout setup with a 9/10 technical rating and 10/10 setup quality, near 52-week highs.","category":"company","datetime":1785492041,"headline":"Revvity (NYSE:RVTY) Flaunts Strong Technical Breakout Setup Near 52-Week High"}, {"id":141069816,"url":"https://finnhub.io/api/news?id=26ef73af2e2d9dd54774b6b3923a4378abfc275210430118f5aef2cae852bbf6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.","category":"company","datetime":1785436199,"headline":"Avantor Stock Surged Because One Segment Stopped Shrinking"}, {"id":141068474,"url":"https://finnhub.io/api/news?id=0597a13729b6d9787ac42ddd83e5f452f49594e62235d6bb08b83ff253b36bb8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?","category":"company","datetime":1785429600,"headline":"Revvity to Report Q2 Earnings: What's in Store for the Stock?"}, {"id":141054224,"url":"https://finnhub.io/api/news?id=43b5f59e24013e85fcec60fb83e0dc40acebb2bce4a3bdf47b1fe522cb3ad553","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1785333622,"headline":"CVS Health (CVS) Earnings Expected to Grow: Should You Buy?"}, {"id":141044137,"url":"https://finnhub.io/api/news?id=a723510fe3b51d20bf2eb9c59cf012529aee854757c52d3735490ccc2f87809e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1785247231,"headline":"Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 4
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 35
discarded_article_count 24
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.4 5/110 48% 2.4
資金流 16.4 20/110 82% 16.4
市場環境 8 15/110 53.33% 8
催化劑 10 20/110 50% 10
風險管理 6.6 10/110 66% 6.6
技術信號 22.6 30/110 75.33% 22.6
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 11/50
ret_5d 0.0588
max_score 50
max_total 50
raw_total 11
vcp_bonus 0
vol_ratio 0.9362
ret_points 8
vol_points 0
range_ratio 0.7362
volat_points 0
day_range_pct 0.0244
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.8972
turnoverUsdM 185.1588
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.RVTY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 115.8728

strength_details

ma_score 1.5
atr_score 2
rsi_score 0.5
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 5.8
take_profit_price 130.4479
target_multiplier 1.9
technical_strength 1.65
take_profit_percent 6.1
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.7945
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.4/5分
資金流分析總分: 16.4/20分
市場環境分析總分: 8/15分
催化劑分析: 10/20分
風險管理總分: 6.6/10分
技術信號分析總分: 22.6/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 3.5636
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.9
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 170.68
cmf
rule Cursor_18.24 CMF bands
level 強累積
score 10
value 0.3561
kdj
d 78.98
j 91.44
k 83.13
rule Cursor_18.24 K/D cross
score 4
signal 金叉
mfi
rule Cursor_18.24 MFI bands
level 強資金流入
score 10
value 74.22
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 6
trend 有流入
value 14799744
recentSlope 232604.4
previousSlope 505340
rsi
value 72.76
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 116.4231
position SAR喺價下
distancePct 5.35
previousTrend 上升
ma50
value 111.609
macd
macd 3.0405
trend 強烈看漲
signal 2.312
histogram 0.7285
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 115.9493
position 連續5日>VWAP
consecutiveAbove 14
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.93
score 4
avgVolume 1615718
currentVolume 1505356
derived
ma20 116.3345
ma50 111.609
prevClose 124.75
avgVolume10 1409316
avgVolume20 1615718
changePercent -1.4
avgVolumeForScore 1615718
ma_cross
ma20 116.3345
ma50 111.609
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 115.588
prevMa50 111.1794
spreadPct 4.23
isVolumeBreakout false
bollinger
lower 108.7723
upper 123.8967
position 上半部
rsi_short
value 69.44
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.93

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.897235772357724,
        "turnoverUsdM": 185.158788,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.RVTY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 115.8728,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.8,
      "take_profit_price": 130.4479,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 6.1
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.794471544715448,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 83,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 72,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 116.3345,
    "ma50": 111.609,
    "close": 123,
    "prevClose": 124.75,
    "avgVolume20": 1615718,
    "volumeRatio": 0.93,
    "changePercent": -1.4
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": 0.058793147972798554,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 0.9362219782885183,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.7362337225006695,
      "volat_points": 0,
      "day_range_pct": 0.024390243902439025,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 83,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 48,
        "contribution": 2.4
      },
      {
        "raw": 16.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 82,
        "contribution": 16.4
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 10,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 22.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 75.33,
        "contribution": 22.6
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "謹慎買入",
    "result": 72,
    "details": [
      "基本面分析總分: 2.4/5分",
      "資金流分析總分: 16.4/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 10/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 22.6/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 10,
      "基本面": 2.4,
      "資金流": 16.4,
      "市場環境": 8,
      "情緒分析": 6,
      "技術信號": 22.6,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 10,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 2
            }
          },
          "catalystPoints": 10
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 185.158788,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 4,
          "mfiPoints": 4,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RVTY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.13
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 710.3985018500001,
                "ma50": 713.2256020399999,
                "name": "QQQ",
                "close": 706.32001,
                "points": 0.4
              },
              "spy": {
                "ma20": 763.5459993000001,
                "ma50": 752.2638036,
                "name": "SPY",
                "close": 763.46997,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.897235772357724,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141202718,
                "url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
                "category": "company",
                "datetime": 1786468489,
                "headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141130140,
                "url": "https://finnhub.io/api/news?id=3b09f71f2cbab477f19820a3c1615fbcc87b1cb019802ccf7fd9d75767be6a7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...",
                "category": "company",
                "datetime": 1785975423,
                "headline": "Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?"
              },
              {
                "id": 141114964,
                "url": "https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.",
                "category": "company",
                "datetime": 1785870540,
                "headline": "RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"
              },
              {
                "id": 141113403,
                "url": "https://finnhub.io/api/news?id=6de21f8800fe1d28710bef6901b16a8e423b3c72a548d7a79f771209813ac706",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.",
                "category": "company",
                "datetime": 1785870203,
                "headline": "Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ..."
              },
              {
                "id": 141112526,
                "url": "https://finnhub.io/api/news?id=f8e2926aa47753dd15c45680ad760e5f6677eb2f3492332a5c7f6542c12951fa",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "Revvity, Inc. (RVTY) Q2 2026 Earnings Call August 4, 2026 7:30 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor Relations & Head of...",
                "category": "company",
                "datetime": 1785854998,
                "headline": "Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141108193,
                "url": "https://finnhub.io/api/news?id=238f072ead1f61789f2adad88d3f819a922309996a3e11aea9ad474b5efb29e9",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Revvity (RVTY) Q2 adjusted EPS beats at $1.41, revenue in line; pro forma FY26 revenue guidance below consensus, stock premarket -0.2%.",
                "category": "company",
                "datetime": 1785847220,
                "headline": "Revvity (NYSE:RVTY) Beats Q2 EPS Estimates, but Soft Revenue Guidance Caps Stock Reaction"
              },
              {
                "id": 141108945,
                "url": "https://finnhub.io/api/news?id=727bdd59352e12f5370f3d9aa1251b4ff5220074e984a861af0bb151406036b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) delivered earnings and revenue surprises of +14.63% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785842703,
                "headline": "Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates"
              },
              {
                "id": 141107927,
                "url": "https://finnhub.io/api/news?id=18c76b227e811cf03590ccb4621a41dfa2eb6c1a394365398cb37b7e9d3264f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785838250,
                "headline": "Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026"
              }
            ],
            "raw_source": [
              {
                "id": 141263724,
                "url": "https://finnhub.io/api/news?id=79817c6765abca477c158dde61718bc04fe3d602b4fecbff929b0a7fcd1bb05a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787252701,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141230562,
                "url": "https://finnhub.io/api/news?id=4d092ebe3aa6f83822c04a961bb022d30ba76830344f6c5fdbe0e95de91c9b2a",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1786857318,
                "headline": "Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside"
              },
              {
                "id": 141218677,
                "url": "https://finnhub.io/api/news?id=652224e6eaeca65523b7fcc05076da4b572b7f65213dd09624d1398b823f11df",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1786721166,
                "headline": "Danaher: 2027 Growth Reacceleration Should Drive Upside"
              },
              {
                "id": 141206709,
                "url": "https://finnhub.io/api/news?id=abf15460060e9d68def7ae24c3778a414925e71cb70a7b8f3956a47e4e500adc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.",
                "category": "company",
                "datetime": 1786629600,
                "headline": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs"
              },
              {
                "id": 141202717,
                "url": "https://finnhub.io/api/news?id=e2a2e352b10892b67e53ab7554bbeb3ba8baff2bbefdfaba1a2267691b1082dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to \"tangible signs of a more constructive spending environmen",
                "category": "company",
                "datetime": 1786587660,
                "headline": "The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call"
              },
              {
                "id": 141202718,
                "url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
                "category": "company",
                "datetime": 1786468489,
                "headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141202719,
                "url": "https://finnhub.io/api/news?id=c4fbd63bd68321a1fd0751f6671df4d112f0dbc162a5bed08991df064ba072e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:",
                "category": "company",
                "datetime": 1786449600,
                "headline": "Revvity to Present at Upcoming Investor Conferences"
              },
              {
                "id": 141174464,
                "url": "https://finnhub.io/api/news?id=63dd3feb8ba49e1ae84ce6a141b45b7a3b89f86583deb193b3dea0bea2fb5247",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.",
                "category": "company",
                "datetime": 1786363200,
                "headline": "Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing"
              },
              {
                "id": 141173746,
                "url": "https://finnhub.io/api/news?id=40b71ceb7b13d365c949f86e7e49081f3457d6ee7e752ab19caba47ee97b41d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1786360642,
                "headline": "1 Profitable Stock on Our Buy List and 2 We Find Risky"
              },
              {
                "id": 141164551,
                "url": "https://finnhub.io/api/news?id=28240c7696bd84e8c1650ca65c32607de843b27341b0f3371fb567d0795f9fd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows",
                "category": "company",
                "datetime": 1786248230,
                "headline": "Revvity Q2 Earnings Call Highlights"
              },
              {
                "id": 141130140,
                "url": "https://finnhub.io/api/news?id=3b09f71f2cbab477f19820a3c1615fbcc87b1cb019802ccf7fd9d75767be6a7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...",
                "category": "company",
                "datetime": 1785975423,
                "headline": "Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?"
              },
              {
                "id": 141124751,
                "url": "https://finnhub.io/api/news?id=60ed1972b305bdd36e0186e5a542aaa8a808486d5b0617cd0227d8d1979e0d48",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.",
                "category": "company",
                "datetime": 1785929351,
                "headline": "Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126"
              },
              {
                "id": 141120490,
                "url": "https://finnhub.io/api/news?id=327874635803840701afed49e7a414cbbd8124be013f75fc7953604475646b8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Moby summary of Revvity, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785893627,
                "headline": "Revvity, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141114964,
                "url": "https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.",
                "category": "company",
                "datetime": 1785870540,
                "headline": "RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"
              },
              {
                "id": 141112773,
                "url": "https://finnhub.io/api/news?id=014a623496be595444b2cd0b07829ee26470d3fd42a2b03f046b0558238ac22f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1785870301,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 141113403,
                "url": "https://finnhub.io/api/news?id=6de21f8800fe1d28710bef6901b16a8e423b3c72a548d7a79f771209813ac706",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.",
                "category": "company",
                "datetime": 1785870203,
                "headline": "Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ..."
              },
              {
                "id": 141110787,
                "url": "https://finnhub.io/api/news?id=a5adcb4f64fad6b04cbe165f0115f21602739e6b7b55d969e069991ad09d0aff",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1785861301,
                "headline": "Discover which S&P500 stocks are making waves on Tuesday."
              },
              {
                "id": 141112950,
                "url": "https://finnhub.io/api/news?id=3c1b90a21300a2c6586eff847edd8a9324cd28249584478e18e22959571d9857",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "2026-08-04. The following slide deck was published by Revvity, Inc.",
                "category": "company",
                "datetime": 1785857544,
                "headline": "Revvity, Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141112526,
                "url": "https://finnhub.io/api/news?id=f8e2926aa47753dd15c45680ad760e5f6677eb2f3492332a5c7f6542c12951fa",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "Revvity, Inc. (RVTY) Q2 2026 Earnings Call August 4, 2026 7:30 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor Relations & Head of...",
                "category": "company",
                "datetime": 1785854998,
                "headline": "Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141109361,
                "url": "https://finnhub.io/api/news?id=25ddbd348ba31eb1ce7b528ec93a8bd8c2ccf96782356409174df68b59475a7a",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1785854101,
                "headline": "Gapping S&P500 stocks in Tuesday's session"
              },
              {
                "id": 141108193,
                "url": "https://finnhub.io/api/news?id=238f072ead1f61789f2adad88d3f819a922309996a3e11aea9ad474b5efb29e9",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Revvity (RVTY) Q2 adjusted EPS beats at $1.41, revenue in line; pro forma FY26 revenue guidance below consensus, stock premarket -0.2%.",
                "category": "company",
                "datetime": 1785847220,
                "headline": "Revvity (NYSE:RVTY) Beats Q2 EPS Estimates, but Soft Revenue Guidance Caps Stock Reaction"
              },
              {
                "id": 141108944,
                "url": "https://finnhub.io/api/news?id=7ede018240307bd8082d76ee22eecddebdc2adfc08739acfb307125d65e8497e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity, Inc. (NYSE:RVTY) reported second-quarter 2026 results that exceeded Wall Street expectations, prompting the health sciences company to raise its guidance for the full year.",
                "category": "company",
                "datetime": 1785846234,
                "headline": "Revvity Tops Second-Quarter Estimates and Lifts Full-Year Outlook"
              },
              {
                "id": 141108945,
                "url": "https://finnhub.io/api/news?id=727bdd59352e12f5370f3d9aa1251b4ff5220074e984a861af0bb151406036b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) delivered earnings and revenue surprises of +14.63% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785842703,
                "headline": "Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates"
              },
              {
                "id": 141107927,
                "url": "https://finnhub.io/api/news?id=18c76b227e811cf03590ccb4621a41dfa2eb6c1a394365398cb37b7e9d3264f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785838250,
                "headline": "Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026"
              },
              {
                "id": 141107928,
                "url": "https://finnhub.io/api/news?id=05a9c470ebcc5ee4fe1783b5505884a609f9c0555e10ea66c747d186160b601f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., August 04, 2026--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026.",
                "category": "company",
                "datetime": 1785837600,
                "headline": "Revvity Announces Financial Results for the Second Quarter of 2026"
              },
              {
                "id": 141111290,
                "url": "https://finnhub.io/api/news?id=a7855707df97a256f43b7df721858f745da5a70746db0b56be898a0f0070be4f",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.\nBenzinga APIs provide real-time access to earnings call transcripts and financial data.",
                "category": "company",
                "datetime": 1785832496,
                "headline": "Transcript: Revvity Q2 2026 Earnings Conference Call"
              },
              {
                "id": 141111291,
                "url": "https://finnhub.io/api/news?id=604e9ed9d00764322ba0a23e6be76962169a7fd5ac737b75d4eaae0d1ddf1bd0",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst estimate. Raises FY2026 sales outlook from $2.810 billion-$2.840 billion to $2.830 billion-$2.860 billion vs $2.858",
                "category": "company",
                "datetime": 1785823346,
                "headline": "Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 Sales Guidance from $2.810B-$2.840B to $2.830B-$2.860B vs $2.858B Est"
              },
              {
                "id": 141111292,
                "url": "https://finnhub.io/api/news?id=a53a734a448eea14c2936b678d1c906fc5fe577a9ef7a904a578fc75abb02862",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.22 by 15.57 percent. This is a 19.49 percent increase over earnings of $1.18 per share from the same",
                "category": "company",
                "datetime": 1785823231,
                "headline": "Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate"
              },
              {
                "id": 141097939,
                "url": "https://finnhub.io/api/news?id=aa35a1e05ff68cc1bfdd32b254910d10f4931cfb4236921bcf0fa7d612164a60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.",
                "category": "company",
                "datetime": 1785737122,
                "headline": "Revvity (RVTY) To Report Earnings Tomorrow: Here Is What To Expect"
              },
              {
                "id": 141082732,
                "url": "https://finnhub.io/api/news?id=6fde63646961578709f68511bafd15d6c771b7b43147b073927253211b00b740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., July 31, 2026--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.",
                "category": "company",
                "datetime": 1785528300,
                "headline": "Revvity Board Declares Quarterly Dividend"
              },
              {
                "id": 141076727,
                "url": "https://finnhub.io/api/news?id=0e9254108a2c029aad9057d72fb6d4e849f4a4c203f61703868c920087b76714",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Revvity (RVTY) shows a strong technical breakout setup with a 9/10 technical rating and 10/10 setup quality, near 52-week highs.",
                "category": "company",
                "datetime": 1785492041,
                "headline": "Revvity (NYSE:RVTY) Flaunts Strong Technical Breakout Setup Near 52-Week High"
              },
              {
                "id": 141069816,
                "url": "https://finnhub.io/api/news?id=26ef73af2e2d9dd54774b6b3923a4378abfc275210430118f5aef2cae852bbf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.",
                "category": "company",
                "datetime": 1785436199,
                "headline": "Avantor Stock Surged Because One Segment Stopped Shrinking"
              },
              {
                "id": 141068474,
                "url": "https://finnhub.io/api/news?id=0597a13729b6d9787ac42ddd83e5f452f49594e62235d6bb08b83ff253b36bb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?",
                "category": "company",
                "datetime": 1785429600,
                "headline": "Revvity to Report Q2 Earnings: What's in Store for the Stock?"
              },
              {
                "id": 141054224,
                "url": "https://finnhub.io/api/news?id=43b5f59e24013e85fcec60fb83e0dc40acebb2bce4a3bdf47b1fe522cb3ad553",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785333622,
                "headline": "CVS Health (CVS) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 141044137,
                "url": "https://finnhub.io/api/news?id=a723510fe3b51d20bf2eb9c59cf012529aee854757c52d3735490ccc2f87809e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247231,
                "headline": "Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 35,
            "discarded_article_count": 24
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.7,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(18.4%→10%)；跌縮量(近10日5日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1488173.3333333333,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1384160,
              "avg_vol_20": 1607905,
              "avg_vol_30": 1488173.3333333333,
              "range_pct_10": 0.09991869918699181,
              "range_pct_20": 0.14219512195121947,
              "range_pct_30": 0.18373983739837393,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9301067079999642,
              "dist_to_20d_high": 0.015763783307993908,
              "down_shrink_days": 5,
              "breakout_level_20d": 124.97,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5438053097345131
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.897235772357724,
              "turnoverUsdM": 185.158788,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.RVTY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 115.8728,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.8,
            "take_profit_price": 130.4479,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 6.1
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.794471544715448,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 3.5636,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.9
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 170.68
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "強累積",
      "score": 10,
      "value": 0.3561
    },
    "kdj": {
      "d": 78.98,
      "j": 91.44,
      "k": 83.13,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 74.22
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 14799744,
      "recentSlope": 232604.4,
      "previousSlope": 505340
    },
    "rsi": 72.76,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 116.4231,
      "position": "SAR喺價下",
      "distancePct": 5.35,
      "previousTrend": "上升"
    },
    "ma50": 111.609,
    "macd": {
      "macd": 3.0405004330589236,
      "trend": "強烈看漲",
      "signal": 2.3120396780368795,
      "histogram": 0.7284607550220441
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 115.9493,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 14
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.93,
      "score": 4,
      "avgVolume": 1615718,
      "currentVolume": 1505356
    },
    "derived": {
      "ma20": 116.3345,
      "ma50": 111.609,
      "prevClose": 124.75,
      "avgVolume10": 1409316,
      "avgVolume20": 1615718,
      "changePercent": -1.4,
      "avgVolumeForScore": 1615718
    },
    "ma_cross": {
      "ma20": 116.3345,
      "ma50": 111.609,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 115.588,
      "prevMa50": 111.1794,
      "spreadPct": 4.23,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 108.7723,
      "upper": 123.8967,
      "position": "上半部"
    },
    "rsi_short": 69.44,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.93
    }
  }
}

Raw metrics JSON

 
{
  "close": 123,
  "volume": 1505356,
  "changePercent": -1.4
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.